10x Genomics Unveils Chromium Xo: A Low-Cost Instrument to Expand Access to High-Performance Single Cell Research [Yahoo! Finance]
10x Genomics, Inc. (TXG)
Last 10x genomics, inc. earnings: 2/18 04:01 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
launch of Chromium Xo, a new addition to its fleet of Chromium single cell instruments. Designed to meet the needs of researchers who desire high-quality data on limited budgets, Chromium Xo offers an affordable entry point into routine, high-performance single cell analysis. "Chromium Xo is the latest in a series of 10x innovations intended to democratize single cell analysis because we never want researchers to have to settle for anything less than the best," said Ben Hindson , Chief Scientific Officer and Co-founder. "With Chromium Xo, we're not just lowering the cost barrier; we're empowering more researchers to achieve high-quality, repeatable results necessary for meaningful scientific breakthroughs." Chromium Xo is 10x Genomics' most affordable single cell instrument, delivering the high-quality data, superior reproducibility and ease of use that the company's instrument-powered workflows are known for, at a U.S. list price of Chromium Xo is specifically designed to run 1
Show less
Read more
Impact Snapshot
Event Time:
TXG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TXG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TXG alerts
High impacting 10x Genomics, Inc. news events
Weekly update
A roundup of the hottest topics
TXG
News
- Lausanne Researchers Combine 10x Genomics' Chromium and Xenium for Novel Insights into Resistance and Potential Therapeutics for Brain CancerPR Newswire
- 10x Genomics, Inc. (NASDAQ: TXG) had its "overweight" rating re-affirmed by analysts at Stephens. They now have a $30.00 price target on the stock.MarketBeat
- 10x Genomics, Inc. (NASDAQ: TXG) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.MarketBeat
- 10x Genomics Unveils Chromium Xo: A Low-Cost Instrument to Expand Access to High-Performance Single Cell ResearchPR Newswire
- 10x Genomics, Inc. (NASDAQ: TXG) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $35.00 price target on the stock.MarketBeat
TXG
Earnings
- 8/8/24 - Beat
TXG
Sec Filings
- 9/4/24 - Form 4
- 8/26/24 - Form 4
- 8/26/24 - Form 4
- TXG's page on the SEC website